Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Merck and Sanofi to Present Three New Studies Highlighting Combination Pediatric Vaccines at IDWeek 2020

10/21/2020 | 07:58am EST

KENILWORTH - The MSP Vaccine Company, a joint venture between Merck, known as MSD outside the United States and Canada, and Sanofi Pasteur, the global vaccines unit of Sanofi, will present new results from three U.S.-based studies at IDWeek 2020, taking place virtually from October 21 to 25.

These studies explore combination pediatric vaccines and highlight parents' perceptions of the vaccination schedule and combination vaccines, physicians' attitudes towards combination vaccines, and variations in co-administration of combination and monovalent vaccines.

'By exploring healthcare professional and parental attitudes toward combination vaccines, we are hoping to better understand the potential utilization of combination vaccinations as well as the barriers that may prevent timeliness and completion of the recommended immunization schedule in infants. We believe the healthcare community will find these studies and their results to be very interesting,' says Michelle Goveia, M.D., Executive Director Medical Affairs at Merck.

'These studies provide important insights into perceptions of physicians and parents on the current use of combination vaccines for infants and children and will hopefully help lead to timely and improved vaccination rates. This is important for now, and in the future, as achieving this goal is challenging given the current pandemic,' says Monica Mercer, M.D., Senior Director Scientific and Medical Affairs at Sanofi Pasteur.

The following abstracts are currently available for meeting attendees viewing, and the full presentations (including audio and/or poster PDFs) will become available on October 21, 2020: Parental Perceptions of the Childhood Vaccination Schedule and Combination Vaccines in the United States (US) Authors: Tanaz Petigara, Xinyi Ng, Ya-Ting Chen, Jyoti Aggarwal, Jenna Bhaloo, Michelle Goveia, David Johnson, Gary Marshall

Abstract: 1399

Session: Poster Session: Pediatric Vaccines, October 21, 2020

Physician Attitudes towards Combination Vaccine Use in Infants up to 24 months of age in the United States Authors: Ya-Ting Chen, Xinyi Ng, Tanaz Petigara, Jyoti Aggarwal, Jenna Bhaloo, Michelle Goveia, David Johnson, Gary Marshall

Abstract: 1400

Session: Poster Session: Pediatric Vaccines, October 21, 2020

Factors Associated with Co-administration of Pentavalent DTaP-IPV/Hib and Monovalent Hepatitis B Vaccine in the United States Authors: Tanaz Petigara, Ya-Ting Chen, Zhiwen Liu, Michelle Goveia, David Johnson, Gary Marshall

Abstract: 1393

Session: Poster Session: Pediatric Vaccines, October 21, 2020

About the MSP Vaccine Company

The MSP Vaccine Company is a U.S.-based joint-partnership between Merck and Sanofi Pasteur, the vaccines unit of Sanofi, and draws upon both companies' experience for the development, manufacturing and marketing of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).

About VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

VAXELIS, the first and only hexavalent vaccine in the U.S., was approved by the Food and Drug Administration in December 2018 and includes antigens for diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis from Sanofi Pasteur and antigens for H. influenzae type b and hepatitis B from Merck. The vaccine is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). Merck and Sanofi are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. VAXELIS product availability is expected mid-2021.

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2019 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contact:

Patrick Ryan

Tel: +1 973-275-7075

Email: Patrick.ryan4@merck.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 1.44% 81.55 Delayed Quote.-10.34%
SANOFI -0.56% 83.78 Real-time Quote.-6.16%
All news about SANOFI
12/01SANOFI : - Dupixent approved by European Commission as first and only biologic m..
AQ
12/01SANOFI : - Update on the intended offer by Sanofi : for Kiadis
AQ
12/01SANOFI : EC approves Dupixent for children aged six to 11 to treat severe atopic..
AQ
12/01France's Ipsen plans $3.6 billion investment in drugs pipeline
RE
11/30SANOFI : Disclosure of trading in own shares
GL
11/30REGENERON PHARMACEUTICALS : Sanofi and Regeneron's Dupixent wins EU approval to ..
RE
11/30SANOFI : Dupixent® (dupilumab) approved by European Commission as first and only..
GL
11/27Ten COVID-19 vaccines seen by mid-year, head of global pharma group says
RE
11/26French health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
More news
Financials
Sales 2020 36 357 M 43 799 M 43 799 M
Net income 2020 11 732 M 14 134 M 14 134 M
Net Debt 2020 7 972 M 9 604 M 9 604 M
P/E ratio 2020 9,03x
Yield 2020 3,80%
Capitalization 106 B 127 B 127 B
EV / Sales 2020 3,13x
EV / Sales 2021 2,95x
Nbr of Employees 100 409
Free-Float 88,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 103,49 €
Last Close Price 84,10 €
Spread / Highest target 40,3%
Spread / Average Target 23,1%
Spread / Lowest Target 1,07%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-6.16%127 364
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415